Lincomycin solution for infusion and intramuscular injection 30%, 1ml No. 10

Infectious and inflammatory diseases of a severe course caused by microorganisms sensitive to lincomycin (especially Staphylococcus spp., Streptococcus spp., Including microorganisms resistant to penicillins, as well as with allergy to penicillins):

• sepsis,

• subacute septic endocarditis,

• lung abscess

• epiema of the pleura,

• pleurisy,

• otitis,

• osteomyelitis (acute and chronic),

• purulent arthritis,

• postoperative purulent complications,

• wound infection

• infections of the skin and soft tissues (pyoderma, furunculosis, phlegmon, erysipelas).

Intramuscularly, for adults, 0.5 g 2 times a day, in severe cases - 0.5 g 3 times a day; children - a daily dose of 15Ц30 mg / kg in 2 injections. Intravenous drip (60-80 drops / min) 0.6 g 3 times a day. The course is 7-14 days, in some cases - up to 1 month.

Solution for i / v and i / m administration 1 ml

lincomycin (as hydrochloride monohydrate)

• Hypersensitivity to lincomycin and clindamycin;

• severe hepatic and / or renal impairment;

• pregnancy (except when it is necessary for health reasons), breastfeeding period, newborns (up to 1 month).

• With care Fungal diseases of the skin, oral mucosa; vagina; myasthenia gravis; simultaneous use with drugs that block neuromuscular conduction; diabetes; hepatic / renal failure of moderate severity; diseases of the gastrointestinal tract, especially colitis, in history.

pharmachologic effect

Antibiotic of the lincosamide group. In therapeutic doses, it acts bacteriostatically. At higher concentrations, it has a bactericidal effect. Suppresses protein synthesis in the microbial cell. It is active mainly against aerobic gram-positive bacteria: Staphylococcus spp. (including strains producing penicillinase), Streptococcus spp. (including Streptococcus pneumoniae / with the exception of Enterococcus faecalis /), Corynebacterium diphtheriae; anaerobic bacteria Clostridium spp., Bacteroides spp. Lincomycin is also active against Mycoplasma spp. Most gram-negative bacteria, fungi, viruses, protozoa are resistant to lincomycin. Resilience is developing slowly. Cross-resistance exists between lincomycin and clindamycin.

Side effect

From the digestive system: nausea, vomiting, diarrhea, abdominal pain, itching of the anus, glossitis, stomatitis, jaundice, transient hyperbilirubinemia, increased activity of hepatic transaminases; with prolonged use - gastrointestinal candidiasis, pseudomembranous colitis.

On the part of the hematopoietic system: reversible leukopenia, thrombocytopenic purpura, neutropenia, agranulotticosis, aplastic anemia and pancytopenia.

Allergic reactions: itching, urticaria, rash, exfoliative dermatitis, vesicular-bullous dermatitis, angioedema, anaphylactic shock, erythema multiforme, Stevens-Johnson syndrome, serum sickness.

From the genitourinary system: impaired renal function (azotemia, oliguria, proteinuria), vaginitis.

From the senses: tinnitus, vertigo. Local reactions: with intravenous administration - thrombophlebitis, with intramuscular administration - local irritation, soreness, formation of a seal and sterile abscess at the injection site.

With rapid intravenous administration: lowering blood pressure, dizziness, headache, drowsiness, general weakness, relaxation of skeletal muscles, respiratory arrest, cardiac arrest.

Application during pregnancy and lactation

Lincomycin crosses the placental barrier, excreted in breast milk. Use during pregnancy is contraindicated. If necessary, use during lactation should decide on the termination of breastfeeding.

Application for violations of liver function

Use is contraindicated in severe liver dysfunction.

Application for impaired renal function

Use is contraindicated in severe renal impairment.

Use in elderly patients

Pharmacokinetics in the elderly with normal liver and kidney function corresponds to the pharmacokinetics of adult patients.

special instructions

In order to avoid the development of aseptic necrosis, it is better to inject deep into the / m. It is impossible to enter IV without preliminary dilution. When signs of pseudomembranous colitis appear (diarrhea, leukocytosis, fever, abdominal pain, excretion of blood and mucus with fecal masses), in mild cases, it is sufficient to discontinue the drug and prescribe ion exchange resins (colestyramine), in severe cases, it is shown to compensate for the loss of fluid, electrolytes and protein, vancomycin - inside, in a daily dose of 0.5-2 g (3-4 admission) for 10 days or bacitracin. The use of drugs that inhibit intestinal motility is contraindicated. Lincomycin is not indicated for the treatment of meningitis because its concentration in the cerebrospinal fluid is insufficient for the treatment of meningitis.It is not recommended to use lincomycin in patients with diabetes mellitus, except in the absence of alternative treatment, since there are no adequate data on the therapy of patients with endocrine or metabolic diseases. T1 / 2 of lincomycin may be increased in patients with impaired liver and kidney function, therefore, caution should be exercised when prescribing lincomycin to patients with hepatic / renal insufficiency of moderate severity and control the concentration of lincomycin in the blood during therapy with high doses of lincomycin. In such patients, the possibility of reducing the frequency of administration of the drug should be considered. Use in patients with hepatic insufficiency is permissible only for health reasons. Against the background of long-term treatment, periodic monitoring of the activity of hepatic transaminases and renal function is necessary.If violations are detected, the possibility of abolishing lincomycin should be considered. As with the use of other antimicrobial drugs, when using lincomycin, especially long-term, it is possible to develop a secondary infection associated with the growth of microorganisms resistant to the drug (especially fungi), to exclude and confirm which the patient's condition should be re-evaluated. If a secondary infection occurs during therapy, the necessary measures should be taken to treat it. Lincomycin should be used with caution in patients with existing fungal diseases, such patients should also be prescribed antifungal therapy.If skin reactions and / or mucosal lesions develop, consult a doctor immediately before continuing treatment with lincomycin.With the use of lincomycin, the development of allergic reactions has been reported, which can progress to a life-threatening condition. In these cases, the use of lincomycin should be discontinued and appropriate treatment initiated. Lincomycin is characterized by neuromuscular conduction blocking activity and may increase muscle weakness in patients with pseudoparalytic myasthenia gravis.

The use of lincomycin in patients with an established diagnosis of pseudoparalytic myasthenia gravis is not recommended

During long-term therapy, periodic blood tests are recommended.

Drug interactions

With simultaneous use with penicillins, cephalosporins, chloramphenicol or erythromycin, antimicrobial antagonism is possible. With simultaneous use with aminoglycosides, synergism of action is possible. With simultaneous use with agents for inhalation anesthesia or muscle relaxants of peripheral action, an increase in neuromuscular blockade is noted, up to the development of apnea. Taking antidiarrheal drugs reduces the effect of lincomycin. With the simultaneous use of theophylline with lincomycin, an inhibitor of the isoenzyme P450, it is possible to increase the effect of theophylline, which may require a decrease in its dose. Pharmaceutical interactions Pharmaceutical incompatible with ampicillin, barbiturates, theophylline, calcium gluconate, heparin and magnesium sulfate.Lincomycin is incompatible with kanamycin or novobiocin in the same syringe or dropper.